These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 18042229)

  • 1. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.
    Freitag FG; Diamond S; Diamond M; Urban G
    Headache; 2008 Feb; 48(2):201-9. PubMed ID: 18042229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
    Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
    Blumenfeld AM; Schim JD; Chippendale TJ
    Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of migraine is a predictor for response to botulinum toxin type A.
    Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW
    Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.
    Evers S; Vollmer-Haase J; Schwaag S; Rahmann A; Husstedt IW; Frese A
    Cephalalgia; 2004 Oct; 24(10):838-43. PubMed ID: 15377314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin type A in prophylactic treatment of migraine.
    Anand KS; Prasad A; Singh MM; Sharma S; Bala K
    Am J Ther; 2006; 13(3):183-7. PubMed ID: 16772757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study.
    Schulte-Mattler WJ; Krack P;
    Pain; 2004 May; 109(1-2):110-4. PubMed ID: 15082132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients.
    Schim J
    Curr Med Res Opin; 2004 Jan; 20(1):49-53. PubMed ID: 14741072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
    Saper JR; Mathew NT; Loder EW; DeGryse R; VanDenburgh AM;
    Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
    Relja M; Poole AC; Schoenen J; Pascual J; Lei X; Thompson C;
    Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT; Kailasam J; Meadors L
    Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin in migraine prophylaxis.
    Göbel H
    J Neurol; 2004 Feb; 251 Suppl 1():I8-11. PubMed ID: 14991336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial.
    Vo AH; Satori R; Jabbari B; Green J; Killgore WD; Labutta R; Campbell WW
    Aviat Space Environ Med; 2007 May; 78(5 Suppl):B113-8. PubMed ID: 17547312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin type A in chronic migraine.
    Freitag FG
    Expert Rev Neurother; 2007 May; 7(5):463-70. PubMed ID: 17492897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine.
    Magalhães E; Menezes C; Cardeal M; Melo A
    Clin Neurol Neurosurg; 2010 Jul; 112(6):463-6. PubMed ID: 20399553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
    J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomized controlled study of the role of botulinum toxin in whiplash-associated disorder.
    Carroll A; Barnes M; Comiskey C
    Clin Rehabil; 2008 Jun; 22(6):513-9. PubMed ID: 18511531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.